



## Novel Target for Pharmacological Treatment of Epilepsy

Guest Editor:

**Dr. Tanveer Singh**

College of Medicine, Texas A&M  
University, Bryan, TX, USA

Deadline for manuscript  
submissions:

**closed (30 April 2024)**

### Message from the Guest Editor

Dear Colleagues,

Epilepsy impacts approximately 65 million individuals across the globe. Roughly 30% of epilepsy patients do not respond well to antiseizure (antiepileptic) medications, leading to the significant therapeutic challenge of managing pharmacoresistant epilepsy. There is an urgent need for the development of more effective epilepsy treatments in order to increase the proportion of patients experiencing life without seizures. Existing drugs target known molecular mechanisms, but the discovery of novel targets and their corresponding ligands holds promise for developing innovative medications, with additional mechanisms of action targeting pharmacoresistant epilepsy.

This Special Issue welcomes research on the discovery of new molecules demonstrating antiepileptic and antiepileptogenic effects. It will also place particular emphasis on potential targets to enable the treatment of benzodiazepine-resistant prolonged seizures. Authors are encouraged to submit original research articles and comprehensive reviews based on in vitro experiments, animal models of seizures with a focus on antiepileptic and antiepileptogenesis molecules, and clinical studies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)